First Human Trial of Oxford Coronavirus Vaccine Shows Promise

- Advertisement -

AstraZeneca’s experimental COVID-19 vaccine was safe and produced an immune response in early-stage clinical trials in healthy volunteers, data showed on Monday.

The vaccine, called AZD1222 and being developed by AstraZeneca and scientists at Britain’s University of Oxford, did not prompt any serious side effects and elicited antibody and T-cell immune responses, according to trial results published in The Lancet medical journal.

AstraZeneca’s is among the leading vaccine candidates against a pandemic that has claimed more than 600,000 lives, alongside others in mid and late-stage trials.

READ  Bahrain: Participation in vaccine trial urged by LMRA chief

These include shots being developed by China’s Sinovac Biotech, another from state-owned Chinese firm Sinopharm, and one from the US biotech firm Moderna.

Comments

- Advertisement -